319 related articles for article (PubMed ID: 30112692)
1. Evolution of adjuvant treatment in endometrial cancer-no evidence and new questions?
Marnitz S; Köhler C; Gharbi N; Kunze S; Jablonska K; Herter J
Strahlenther Onkol; 2018 Nov; 194(11):965-974. PubMed ID: 30112692
[TBL] [Abstract][Full Text] [Related]
2. Lymphadenectomy in women with endometrial cancer: aspiration and reality from a radiation oncologist's point of view.
Foerster R; Kluck R; Arians N; Rieken S; Rief H; Adeberg S; Bostel T; Schlampp I; Debus J; Lindel K
Radiat Oncol; 2015 Jul; 10():147. PubMed ID: 26179059
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant chemotherapy in endometrial cancer.
Gómez-Raposo C; Merino Salvador M; Aguayo Zamora C; Casado Saenz E
Cancer Chemother Pharmacol; 2020 Mar; 85(3):477-486. PubMed ID: 31950214
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant treatment improves overall survival in women with high-intermediate risk early-stage endometrial cancer with lymphovascular space invasion.
Son J; Chambers LM; Carr C; Michener CM; Yao M; Beavis A; Yen TT; Stone RL; Wethington SL; Fader AN; Burkett WC; Richardson DL; Staley AS; Ahn S; Gehrig PA; Torres D; Dowdy SC; Sullivan MW; Modesitt SC; Watson C; Veade A; Ehrisman J; Havrilesky L; Secord AA; Loreen A; Griffin K; Jackson A; Viswanathan A; Ricci S
Int J Gynecol Cancer; 2020 Nov; 30(11):1738-1747. PubMed ID: 32771986
[TBL] [Abstract][Full Text] [Related]
5. Substantial lymph-vascular space invasion (LVSI) is a significant risk factor for recurrence in endometrial cancer--A pooled analysis of PORTEC 1 and 2 trials.
Bosse T; Peters EE; Creutzberg CL; Jürgenliemk-Schulz IM; Jobsen JJ; Mens JW; Lutgens LC; van der Steen-Banasik EM; Smit VT; Nout RA
Eur J Cancer; 2015 Sep; 51(13):1742-50. PubMed ID: 26049688
[TBL] [Abstract][Full Text] [Related]
6. Isolated tumor cells identified by sentinel lymph node mapping in endometrial cancer: Does adjuvant treatment matter?
Plante M; Stanleigh J; Renaud MC; Sebastianelli A; Grondin K; Grégoire J
Gynecol Oncol; 2017 Aug; 146(2):240-246. PubMed ID: 28577885
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant therapy in stage III endometrial cancer: treatment outcomes and survival. a single-institution retrospective study.
Kuku S; Williams M; McCormack M
Int J Gynecol Cancer; 2013 Jul; 23(6):1056-64. PubMed ID: 23765205
[TBL] [Abstract][Full Text] [Related]
8. Impact of different adjuvant treatment approaches on survival in stage III endometrial cancer: A population-based study.
van Weelden WJ; Reijnen C; Eggink FA; Boll D; Ottevanger PB; van den Berg HA; van der Aa MA; Pijnenborg JMA
Eur J Cancer; 2020 Jul; 133():104-111. PubMed ID: 32454416
[TBL] [Abstract][Full Text] [Related]
9. Maintained survival outcome after reducing lymphadenectomy rates and optimizing adjuvant treatment in endometrial cancer.
Forsse D; Berg HF; Bozickovic O; Engerud H; Halle MK; Hoivik EA; Woie K; Werner HMJ; Haldorsen IS; Trovik J; Krakstad C
Gynecol Oncol; 2021 Feb; 160(2):396-404. PubMed ID: 33317908
[TBL] [Abstract][Full Text] [Related]
10. Outcomes of stage II endometrial cancer: The UPMC Hillman Cancer Center experience.
Chen KS; Berhane H; Gill BS; Olawaiye A; Sukumvanich P; Kelley JL; Boisen MM; Courtney-Brooks M; Comerci JT; Edwards R; Berger J; Beriwal S
Gynecol Oncol; 2017 Nov; 147(2):315-319. PubMed ID: 28866431
[TBL] [Abstract][Full Text] [Related]
11. Postoperative external beam radiation therapy and concurrent cisplatin followed by carboplatin/paclitaxel for stage III (FIGO 2009) endometrial cancer.
Milgrom SA; Kollmeier MA; Abu-Rustum NR; Tew WP; Sonoda Y; Barakat RR; Alektiar KM
Gynecol Oncol; 2013 Sep; 130(3):436-40. PubMed ID: 23800696
[TBL] [Abstract][Full Text] [Related]
12. Nomograms for prediction of outcome with or without adjuvant radiation therapy for patients with endometrial cancer: a pooled analysis of PORTEC-1 and PORTEC-2 trials.
Creutzberg CL; van Stiphout RG; Nout RA; Lutgens LC; Jürgenliemk-Schulz IM; Jobsen JJ; Smit VT; Lambin P
Int J Radiat Oncol Biol Phys; 2015 Mar; 91(3):530-9. PubMed ID: 25680597
[TBL] [Abstract][Full Text] [Related]
13. Lymph-vascular space invasion and number of positive para-aortic node groups predict survival in node-positive patients with endometrial cancer.
Watari H; Todo Y; Takeda M; Ebina Y; Yamamoto R; Sakuragi N
Gynecol Oncol; 2005 Mar; 96(3):651-7. PubMed ID: 15721407
[TBL] [Abstract][Full Text] [Related]
14. Updates on adjuvant chemotherapy and radiation therapy for endometrial cancer.
Cowan M; Strauss JB; Barber EL; Matei D
Curr Opin Obstet Gynecol; 2019 Feb; 31(1):31-37. PubMed ID: 30571659
[TBL] [Abstract][Full Text] [Related]
15. [Synchronous primary cancers of the endometrium and ovary: review of 43 cases].
Ma SK; Zhang HT; Sun YC; Wu LY
Zhonghua Zhong Liu Za Zhi; 2008 Sep; 30(9):690-4. PubMed ID: 19173912
[TBL] [Abstract][Full Text] [Related]
16. Current therapy of patients with endometrial carcinoma. A critical review.
Marnitz S; Köhler C
Strahlenther Onkol; 2012 Jan; 188(1):12-20. PubMed ID: 22189438
[TBL] [Abstract][Full Text] [Related]
17. Lymphovascular Invasion in Endometrial Cancer: Prognostic Value and Implications on Adjuvant Radiation Therapy Use.
Boothe D; Wolfson A; Christensen M; Francis S; Werner TL; Gaffney DK
Am J Clin Oncol; 2019 Jul; 42(7):549-554. PubMed ID: 31169554
[TBL] [Abstract][Full Text] [Related]
18. Survival Analysis of Cancer Patients With FIGO Stage IIIA Endometrial Cancer.
Lum MM; Belnap TW; Frandsen J; Brown AP; Sause WT; Soisson AP; Dodson MK; Werner T; Gaffney DK
Am J Clin Oncol; 2015 Jun; 38(3):283-8. PubMed ID: 23774072
[TBL] [Abstract][Full Text] [Related]
19. Oncological Outcomes of Stage II Endometrial Cancer: A Retrospective Analysis of 250 Cases.
Ozgul N; Boyraz G; Salman MC; Gultekin M; Yuce K; Ibrahimov A; Erturk A; Gungorduk K; Gulseren V; Sanci M; Turkmen O; Karalok A; Kimyon G; Turan T; Ozkan NT; Meydanli MM; Gungor T; Ayik H; Simsek T
Int J Gynecol Cancer; 2018 Jan; 28(1):161-167. PubMed ID: 28930810
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant Treatment after Surgery in Stage IIIA Endometrial Adenocarcinoma.
Yoon MS; Huh SJ; Kim HJ; Kim YS; Kim YB; Kim JY; Lee JH; Kim HJ; Cha J; Kim JH; Kim J; Yoon WS; Choi JH; Chun M; Choi Y; Lee KK; Kim M; Jeong JU; Chang SK; Park W
Cancer Res Treat; 2016 Jul; 48(3):1074-83. PubMed ID: 26511800
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
